SCHEDULE 13G
This Schedule 13G (this “Schedule 13G”) relates to shares of Ordinary Shares, par value NIS 0.16 (“Ordinary Shares”), of Foamix Pharmaceuticals Ltd., a company incorporated under the laws of the State of Israel (the “Issuer”), and is being filed on behalf of (i) Delaware Street Capital Master Fund, L.P. (the “Fund”), a Cayman Islands exempted limited partnership, (ii) DSC Advisors, L.P. (“DSCA”), a Delaware limited partnership, as investment manager to the Fund, (iii) DSC Managers, L.L.C. (“DSCM”), a Delaware limited liability company, as the general partner of the Fund, (iv) DSC Advisors, L.L.C. (“DSCA LLC”), a Delaware limited liability company, as the general partner of DSCA, and (v) Andrew G. Bluhm, the principal of DSCA LLC (the persons mentioned in (ii), (iii), (iv) and (v) above are referred to herein as the “Delaware Street Capital Group,” and, together with the Fund, the “Reporting Persons”). All of the Ordinary Shares are held by the Fund.
Foamix Pharmaceuticals Ltd.
Item 1(b) | Address of Issuer’s Principal Executive Offices. |
2 Holzman Street, Weizmann Science Park
Rehovot 7670402, Israel
Item 2(a) | Name of Person Filing. |
(i) Delaware Street Capital Master Fund, L.P., (ii) DSC Advisors, L.P. (iii) DSC Managers, L.L.C, (iv) DSC Advisors, L.L.C. and (v) Andrew G. Bluhm.
Item 2(b) | Address of Principal Business Office, or, if none, Residence. |
900 North Michigan, Suite 1600
Chicago, IL 60611
Item 2(c) | Citizenship or Place of Organization. |
The Fund is a Cayman Islands exempted limited partnership. DSCA is a Delaware limited partnership. DSCM is a Delaware limited liability company. DSCA LLC is a Delaware limited liability company. Mr. Bluhm is a United States citizen.
Item 2(d) | Title of Class of Securities. |
Ordinary Shares, par value NIS 0.16 (the “Ordinary Shares”).
M46135105
7